CTI BioPharma Income Statement

Financials in millions ILS. Fiscal year is January - December.

Millions ILS. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Selling, General & Admin	2.96	4.91	7.9	8.13	0.62	Upgrade
Research & Development	4.9	5.4	8.08	6.54	0.77	Upgrade
Other Operating Expenses	-	0.35	0.77	0	-	Upgrade
Operating Expenses	7.86	10.66	16.74	14.67	1.4	Upgrade
Operating Income	-7.86	-10.66	-16.74	-14.67	-1.4	Upgrade
Interest Expense	-0.22	-0.45	-0.36	-0.28	-0.01	Upgrade
Interest & Investment Income	0.04	0.17	-	-	0	Upgrade
Currency Exchange Gain (Loss)	-0.01	0.02	0.03	-0.02	-0.03	Upgrade
Other Non Operating Income (Expenses)	-0.01	-0	-0.01	-129.24	-0	Upgrade
EBT Excluding Unusual Items	-8.06	-10.93	-17.08	-144.21	-1.44	Upgrade
Gain (Loss) on Sale of Assets	-0.37	-	-	-	-	Upgrade
Asset Writedown	-0.07	-	-	-	-	Upgrade
Pretax Income	-8.51	-10.93	-17.08	-144.21	-1.44	Upgrade
Net Income	-8.51	-10.93	-17.08	-144.21	-1.44	Upgrade
Net Income to Common	-8.51	-10.93	-17.08	-144.21	-1.44	Upgrade
Shares Outstanding (Basic)	69	61	50	37	9	Upgrade
Shares Outstanding (Diluted)	69	61	50	37	9	Upgrade
Shares Change (YoY)	13.26%	21.99%	35.68%	302.81%	589.59%	Upgrade
EPS (Basic)	-0.12	-0.18	-0.34	-3.92	-0.16	Upgrade
EPS (Diluted)	-0.12	-0.18	-0.34	-3.92	-0.16	Upgrade
Free Cash Flow	-6.14	-10.22	-14.41	-12.1	-1.74	Upgrade
Free Cash Flow Per Share	-0.09	-0.17	-0.29	-0.33	-0.19	Upgrade
EBITDA	-6.51	-10.21	-16.31	-14.51	-1.39	Upgrade
D&A For EBITDA	1.35	0.45	0.43	0.17	0	Upgrade
EBIT	-7.86	-10.66	-16.74	-14.67	-1.4	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.